Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioblastoma × mirdametinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 2 Colorectal Neoplasms 2 Vascular Malformations 1 Skin Diseases, Vascular 1 Primary Malignant Peripheral Nerve Sheath Tumors 1 Oligodendroglioma 1 Neurofibromatoses 1 Neurofibroma 1 Neurocytoma 1 Neoplasms, Neuroepithelial 1 NF1 1 Melanoma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Liposarcoma, Myxoid 1 Liposarcoma 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Glioma 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Breast Neoplasms 1 Astrocytoma 1 Arteriovenous Malformations 1

Interventions

Temozolomide 264 Radiotherapy 119 Bevacizumab 104 Magnetic Resonance Spectroscopy 58 Radiation 47 pembrolizumab 30 Irinotecan 28 Surgical Procedures, Operative 23 Lomustine 21 Nivolumab 19 Specimen Handling 18 Radiosurgery 18 Carmustine 18 Aminolevulinic Acid 16 Erlotinib Hydrochloride 15 Drug Therapy 14 Radiotherapy, Intensity-Modulated 13 O(6)-benzylguanine 13 Chemotherapy, Adjuvant 13 Carboplatin 13 Blood Specimen Collection 13 Filgrastim 11 Cyclophosphamide 11 sargramostim 10 poly ICLC 10 Thalidomide 10 Etoposide 10 atezolizumab 9 Ipilimumab 9 Everolimus 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡